Insulin Resistance Market

Market Overview:

The 7 major insulin resistance markets reached a value of USD 26.9 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 64.8 Billion by ​2035​, exhibiting a growth rate (CAGR) of 8.33% during ​2025-2035​.

The insulin resistance market has been comprehensively analyzed in IMARC's new report titled "Insulin Resistance Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Insulin resistance is a pathological disease in which cells in insulin-sensitive tissues in the body do not respond normally to the hormone insulin or downregulate insulin receptors in response to hyperinsulinemia. Insulin resistance can cause hyperglycemia, hypertension, dyslipidemia, hyperuricemia, increased inflammatory markers, endothelial dysfunction, and thrombosis. The most common result of this ailment is type 2 diabetes. Some common symptoms associated with insulin resistance include increased thirst, frequent urination, fatigue, and blurred vision due to high blood sugar. Additionally, individuals may experience weight gain, darkened skin patches, difficulty concentrating, mood swings, anxiety, and increased hunger. The diagnosis of this condition typically involves blood testing, physical exams, and risk factor assessments. The healthcare provider also recommends blood tests, like fasting plasma glucose (FPG), that can screen for prediabetes, type 2 diabetes, or gestational diabetes in patients. Numerous other indicators include waist circumference (more than 40 inches in men and 35 inches in women), skin tags, high blood pressure, and high triglycerides.

The escalating prevalence of obesity, particularly visceral fat (around organs), which triggers a cascade of events that impair the body's ability to respond to insulin, is primarily driving the insulin resistance market. In addition to this, the inflating utilization of thiazolidinediones, like rosiglitazone and pioglitazone, since they work by increasing insulin sensitivity in skeletal muscle and adipose tissue to improve glucose control, is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications, including regular physical activity, weight management, and a healthy diet, for reducing the risk of developing type 2 diabetes and mitigating the complications associated with insulin resistance, is further bolstering the market growth. Apart from this, the rising usage of omega-3 fatty acids therapy on account of its numerous benefits, such as decreased inflammation, boosted lipid metabolism, and enhanced mitochondrial function, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy to optimize insulin signaling in adipose tissue by modulating genes involved in glucose metabolism is expected to drive the insulin resistance market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the insulin resistance market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for insulin resistance and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the insulin resistance market in any manner.

Recent Developments:

• In February 2025, Novo Nordisk said that the U.S. Food and Drug Administration (FDA) declared that the Wegovy and Ozempic shortages had been resolved. The FDA's assessment showed that the supply of prescription-only GLP-1 medications in the United States now meets or exceeds both current and projected demand.
• In August 2024, Eli Lilly and Company reported favorable topline results from the three-year, 176-week SURMOUNT-1 study, which evaluated the safety and effectiveness of tirzepatide (Zepbound and Mounjaro) once weekly for long-term weight control and preventing the progression of diabetes in adults who are overweight, obese, or pre-diabetic. When compared to placebo, weekly tirzepatide injections (5 mg, 10 mg, 15 mg) substantially decreased the likelihood of developing type 2 diabetes by 94% in those with pre-diabetes, obesity, or overweight.

Drugs:

Fortamet (metformin hydrochloride) lowers blood sugar primarily by reducing hepatic glucose production (gluconeogenesis) and increasing insulin sensitivity. It also inhibits the absorption of glucose in the intestines and enhances peripheral glucose uptake and utilization. Fortamet achieves this by activating AMPK, a key cellular regulator of metabolism, which in turn modulates lipid metabolism and reduces the expression of gluconeogenic enzymes.

Actos (pioglitazone) is a thiazolidinedione, a class of medications that helps improve insulin sensitivity. The drug works by activating a specific nuclear receptor called peroxisome proliferator-activated receptor-gamma (PPAR-gamma). This activation triggers changes in gene expression, leading to the production of proteins that enhance insulin sensitivity. By improving insulin sensitivity, Actos helps cells utilize glucose more efficiently, reducing blood sugar levels.

Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily improves insulin sensitivity and reduces blood sugar by mimicking GLP-1's actions. It enhances insulin secretion in response to elevated glucose, suppresses glucagon secretion, and may slow gastric emptying, all contributing to better glycemic control and, in some cases, weight loss.

Mounjaro (tirzepatide) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The drug boosts insulin secretion, reduces glucagon levels, delays gastric emptying, and promotes satiety, leading to improved glycemic control and weight loss. It also enhances insulin sensitivity in peripheral tissues and increases adiponectin levels, which helps reduce inflammation and improve metabolic function, making it effective for managing insulin resistance and related metabolic disorders.

(PEG)-BHD1028 is a PEGylated peptide developed by EncuraGen that functions as an adiponectin receptor agonist, targeting AdipoR1 and AdipoR2. By binding to these receptors, it activates the AMPK and PPARα signaling pathways, enhancing glucose uptake, fatty acid β-oxidation, and mitochondrial biogenesis. This mechanism effectively reduces insulin resistance and improves metabolic profiles.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the insulin resistance market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the insulin resistance market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current insulin resistance marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the insulin resistance market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the insulin resistance across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the insulin resistance across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of insulin resistance across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of insulin resistance by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of insulin resistance by gender across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of insulin resistance by type across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with insulin resistance across the seven major markets?
• What is the size of the insulin resistance patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend insulin resistance of?
• What will be the growth rate of patients across the seven major markets?

Insulin Resistance: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for insulin resistance drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the insulin resistance market?
• What are the key regulatory events related to the insulin resistance market?
• What is the structure of clinical trial landscape by status related to the insulin resistance market?
• What is the structure of clinical trial landscape by phase related to the insulin resistance market?
• What is the structure of clinical trial landscape by route of administration related to the insulin resistance market?